Home > Neurology > MTIS 2020 > Contents > Improvement of migraine using CGRP mAbs in a real-world setting

Improvement of migraine using CGRP mAbs in a real-world setting

Presented By
Prof. Robert E. Shapiro, University of Vermont, VT, USA
Conference
MTIS 2020
Trial
OVERCOME
  Most patients taking a calcitonin gene-related peptide (CGRP)-targeted monoclonal antibody (mAb) for the preventive treatment of migraine reported their migraine condition as better since starting the medication. This improvement appears relatively consistent across monthly headache day categories. Real-world patient-reported outcome data is limited for patients who use a CGRP mAb for the preventive treatment of migraine. The current study, presented by Dr Robert Shapiro (University of Vermont, USA), assessed patient characteristics and patient-reported improvement among current users of CGRP mAbs [1]. Data was obtained in the last quarter of 2019 as part of the OVERCOME study via a web-based survey conducted in a representative US sample. Over 20,000 respondents were selected via a validated migraine diagnostic screener for International Classification of Headache Disorders, 3rd edition (ICHD-3) criteria (95.1% of ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on